Experience

Davis Polk advised the joint book-running managers in connection with a registered offering by Eli Lilly and Company of $1.1 billion aggregate principal amount of senior notes, consisting…

Davis Polk advised CureVac N.V. on its $245.3 million initial public offering of 15,333,332 of its common shares, which includes 1,999,999 common shares from the full exercise of the…

Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Five Prime Therapeutics, Inc. of its common stock for up to an aggregate amount of $75 million. Five…

Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $125 million public offering of common stock by Personalis, Inc. The common stock…

Davis Polk advised the sales agent on the SEC-registered at-the-market offering by IDEAYA Biosciences, Inc. of its common stock for up to an aggregate amount of $50 million. Based in…

Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Atreca, Inc. of its common stock for up to an aggregate amount of $100 million. Atreca is a…

Davis Polk advised Freeline Therapeutics Holdings plc on its $158.8 million initial public offering of 8,823,529 American depositary shares representing 8,823,529 ordinary shares, which…

Davis Polk advised the representatives of the underwriters in connection with an approximately $963.5 million public offering of ordinary shares of Horizon Therapeutics Public Limited…

Davis Polk advised Acutus Medical, Inc. on its SEC-registered initial public offering of 10,147,058 shares of common stock for an aggregate price to the public of approximately $170 million…

Davis Polk advised the joint book running managers in connection with the $377.3 million initial public offering of 17,968,750 shares of common stock of Oak Street Health, Inc., which…